Sub:- Allotment of 1,55,000 Equity Shares of Rs.2/- each under NATCO Employee Stock Option Scheme, 2017 (NATSOP 2017)
This to inform that the Compensation Committee of the Board of Directors of the Company has allotted 1,55,000 equity shares of Rs.2/- each (Face Value) on 28th January, 2022 by way of resolution passed by circulation to the eligible employees who had exercised their vested options under the Company's Employee Stock Option Scheme, 2017. The said equity shares shall rank Parri-passu with the existing equity shares of the Company in all respects including dividends and corporate benefits, if any, to be declared by the Company.
Resultantly, the paid-up share capital of the Company will be Rs.36,50,40,330/- (Rupees Thirty-Six Crores Fifty Lakhs Forty Thousand Three Hundred and Thirty only) divided into 18,25,20,165 equity shares of Rs.2/- each.
You are requested to kindly take the same on record.
Thanking you
Yours faithfully
For NATCO Pharma Limited
ADINARAYAN A MADINEEDI
Digitally signed by ADINARAYANA MADINEEDI DN: c=IN, st=Telangana, 2.5.4.20=a008497813275d4124d2b42c9f7f924b5b96346aa8741a90d57 d102d95c690c8, postalCode=500017, street=12-13-266 street no 2 Lane no 9 Tarnaka secunderabad, pseudonym=52398da71daa6f1de479ec9618474b70, serialNumber=3da487f04b8912870dea3f277d9e87fc06da96e80b36d2b eb1428dfe3f665de7, o=Personal, cn=ADINARAYANA MADINEEDI Date: 2022.01.28 14:41:17 +05'30'
M Adinarayana
Company Secretary & Vice President
(Legal & Corporate Affairs)
Attachments
Original Link
Original Document
Permalink
Disclaimer
Natco Pharma Limited published this content on 28 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 January 2022 10:17:03 UTC.
Natco Pharma Limited is an India-based vertically integrated pharmaceutical company with focus on research and development. The Company is engaged in in the development, manufacturing and commercialization of complex pharmaceuticals that target specific therapeutic areas. It specializes in catering to niche markets and offering solutions to address complex medical needs. It owns nine manufacturing facilities across India and two research centers in Telangana. The Companyâs segment includes Pharmaceuticals and Agro chemicals. Its Pharmaceuticals segment is engaged in manufacturing and selling of bulk drugs, finished dosage formulations and related services. Its Agro Chemicals is engaged in manufacturing and selling of agro chemical. It manufactures active pharmaceutical ingredients products which are primarily used for captive consumption in its FDF products and are also sold to customers for various international markets such as Brazil, Europe, and United States of America.
NATCO PHARMA LIMITED 
